Loading…
Please register to continue your trial period!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
NuBiyota develops Microbial Ecosystem Therapeutics (MET), focusing on multi-strain consortia derived from "super donors" for indications such as gastrointestinal diseases. Their platform emphasizes standardization and the creation of defined, complex microbial communities for therapeutic use. NuBiyota has established partnerships with companies like Takeda for research and development of microbiome-based therapies. It’s approach centers on isolating and culturing strains from individual "super donors" to create standardized, multi-strain therapeutics
Source: Company information
see also:
[Microbial Ecosystem Therapeutics (MET)](brain://vSpd9lwLa0O2ijumFUlS9g/MicrobialEcosystemTherape…